Company Filing History:
Years Active: 2011-2022
Title: Kyung Aih Kang: Innovator in Nanoparticle Technology
Introduction
Kyung Aih Kang is a notable inventor based in Louisville, KY (US). He has made significant contributions to the field of nanoparticle technology, particularly in the development of compositions for cancer treatment. With a total of 7 patents, his work is recognized for its innovative approach to medical applications.
Latest Patents
One of his latest patents involves anti-nucleolin agent-conjugated nanoparticles. This composition comprises an anti-nucleolin agent that is conjugated to nanoparticles, which are non-magnetic, not iron oxide, and not polyacrylamide. Furthermore, this pharmaceutical composition is designed for treating cancer and includes a composition that combines the anti-nucleolin agent with nanoparticles and a pharmaceutically acceptable carrier.
Career Highlights
Kyung Aih Kang is affiliated with the University of Louisville Research Foundation, Inc. His work has been pivotal in advancing the understanding and application of nanoparticles in medical treatments. His innovative research continues to pave the way for new therapeutic strategies.
Collaborations
Some of his notable coworkers include Paula J Bates and Mohammad Tariq Malik. Their collaborative efforts contribute to the ongoing research and development in the field of nanoparticle technology.
Conclusion
Kyung Aih Kang's contributions to nanoparticle technology and cancer treatment exemplify the impact of innovative research in medicine. His work continues to inspire advancements in therapeutic applications.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.